A commemorative symposium of Japan Sarcoma Association is to be held in Kyoto on December 3 and 4. NPO Cure Sarcoma supports this symposium.
If you would like to participate in this seminar, please send an application by November 16 to jsa@smtrc.org (e-mail) or 06-6981-3000 (fax). Participants need to be a member of Cure Sarcoma Center with an annual membership fee of 15,000 yen. (Two people can attend the seminar.)
For the details, please see below:
Title of symposium:
Rare Cancer Sarcoma – Milestones for Conquering Sarcoma
Place:
Kyoto Heian Hotel 2F
Date:
December 3 (Thursday) 9 a.m. to 5 p.m.
Cutting Edge Lecture
Educational Lecture
Luncheon Seminar
Symposium 1
Symposium 2
Poster Session/Patients advocacy/Exhibition
Gala Dinner/Banquet (7,000 yen)
December 4 (Friday) 7:40 a.m. to 12 noon
Morning Lecture
Symposium 3
Monthly Archives: October 2015
Novel Antitumor Agent “Yondelis® IV Infusion” Approved in Japan for Treatment of Soft Tissue Sarcoma
Taiho Pharmaceutical Co., Ltd. announced on September 28 that it received marketing approval from the Ministry of Health, Labour and Welfare for the novel antitumor agent Yondelis (nonproprietary name: trabectedin) 0.25 mg and 1 mg IV Infusion, for the treatment of patients with soft tissue sarcoma in Japan.
Yondelis is an antitumor agent developed by the Spanish company PharmaMar, S.A. It was originally isolated from the Caribbean ascidian Ecteinascidia turbinata and is now produced through semi-synthesis. Taiho Pharmaceutical entered into a license agreement with PharmaMar in 2009 to develop and commercialize the drug in Japan, and has since been engaged in its development.
http://www.taiho.co.jp/english/news/20150928.html